Abbisko Therapeutics Co. Ltd. has patented epidermal growth factor receptor (EGFR; HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.

Recent Pipeline Therapeutics Inc. patents describe lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of cancer, encephalitis, scleroderma, nonalcoholic steatohepatitis (NASH), multiple sclerosis, hepatic fibrosis, idiopathic pulmonary fibrosis and neurodegenerative diseases, among others.

Previous studies indicated a protective function of TNFR2 signaling in multiple sclerosis (MS) as well as experimental autoimmune encephalomyelitis.

Atopic dermatitis (AD) is an inflammatory skin disease with complex pathogenesis. Researchers from the Swiss Institute of Allergy and Asthma Research and their collaborators have investigated biomarkers tied to AD and its severity.

Touchlight Genetics Ltd. has announced FDA clearance of an IND application for a product utilizing doggybone DNA (dbDNA).

Incyclix Bio LLC has received FDA approval of an IND application for INX-315, a novel, potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for advanced or metastatic cancers. The first-in-human phase I/II study will be conducted in patients with estrogen receptor (ER)-positive/HER2-negative breast cancer who have progressed on a CDK4/6 inhibitor regimen and CCNE1-amplified solid tumors that have progressed on standard-of-care treatment.

Prior to the COVID-19 pandemic, tuberculosis ranked as the leading cause of infectious disease deaths worldwide; the increase of multidrug-resistant Mycobacterium tuberculosis puts some pressure on the search for new tuberculosis therapeutic approaches. Researchers from Sanofi SA and their collaborators have published preclinical results on a sequanamycin – sequanamycin 9 (SEQ-9) – for the potential treatment of tuberculosis.